Benzodiazepine Medications Compared
Benzodiazepines are a class of central nervous system depressants that have been in clinical use since the 1960s. They are among the most widely prescribed drug classes in the United States, used for anxiety disorders, insomnia, seizure disorders, alcohol withdrawal, muscle spasm, and procedural sedation. Despite sharing a common mechanism of action, individual benzodiazepines differ dramatically in their speed of onset, duration of effect, potency, and the presence of pharmacologically active metabolites — differences that have profound practical significance in matching the right drug to the right patient.
This guide covers every major benzodiazepine currently available in the United States, their pharmacokinetic properties, available strengths, DEA schedule status, and clinical use cases, along with a discussion of risks, the Z-drug class, and practical patient selection guidance.
⚠ NEVER STOP ABRUPTLY — Benzodiazepine withdrawal can be fatal. Seizures and death have occurred when these medications were stopped suddenly after regular use. Never discontinue a benzodiazepine without medical supervision and a gradual taper plan.
⚠ OPIOID + BENZO COMBINATION — Taking benzodiazepines together with opioids (such as oxycodone, hydrocodone, morphine, methadone, or tramadol) dramatically increases the risk of respiratory depression, sedation, and death. This combination has been identified by the FDA as one of the leading causes of overdose death in the United States. If you are prescribed both, discuss alternatives with your prescriber.
How Benzodiazepines Work: The GABA-A Mechanism
Benzodiazepines work by binding to a specific site on the GABA-A receptor — a ligand-gated chloride ion channel that is the primary inhibitory receptor in the central nervous system. GABA (gamma-aminobutyric acid) is the brain's main inhibitory neurotransmitter; when GABA binds to its receptor, it opens the chloride channel and hyperpolarizes the neuron, reducing the likelihood of the neuron firing.
Benzodiazepines do not activate GABA-A receptors on their own. Instead, they act as positive allosteric modulators — they bind to a separate site on the receptor and enhance the effect of GABA that is already present. When a benzodiazepine is present, the same amount of GABA produces a larger opening of the chloride channel and a greater inhibitory effect. This is distinct from barbiturates, which can directly activate the GABA-A receptor without GABA being present (a key reason barbiturates carry higher overdose risk than benzodiazepines in isolation).
The result of enhanced GABA activity is widespread CNS depression: reduced anxiety, sedation, muscle relaxation, anticonvulsant effects, and anterograde amnesia (impaired formation of new memories after taking the drug). Different GABA-A receptor subunit combinations are found in different brain regions, which is why different benzodiazepines — and different doses of the same benzodiazepine — may emphasize these effects to varying degrees.
Key concept: Potency vs. Duration. Two properties of benzodiazepines are commonly confused. Potency refers to how much drug is needed to produce a given effect — high-potency benzos like alprazolam and clonazepam require much smaller milligram amounts than low-potency benzos like diazepam. Duration refers to how long effects last, which is primarily determined by half-life and the presence of active metabolites. A drug can be high-potency and short-acting (alprazolam), high-potency and long-acting (clonazepam), or low-potency and long-acting (diazepam).
Individual Drug Profiles
Alprazolam is the most prescribed benzodiazepine in the United States. It is short-acting and high-potency — one of the most potent benzodiazepines available — with rapid onset that makes it effective for acute anxiety and panic attacks. Its short half-life (6–12 hours) means effects wear off relatively quickly, which can lead to interdose rebound anxiety, a phenomenon where anxiety symptoms return or worsen between doses. This rebound pattern is a significant driver of dose escalation and dependence with alprazolam.
Alprazolam XR (extended-release) was developed to address some of these rebound issues by delivering the drug more slowly over a longer period, producing a smoother pharmacokinetic curve. Alprazolam is FDA-approved for panic disorder and generalized anxiety disorder. It is not approved for seizure management. Generic alprazolam is widely available.
Diazepam is one of the original benzodiazepines and remains the reference standard against which other benzos are compared (diazepam equivalency is the common unit for benzo potency comparisons). It is long-acting, with a parent drug half-life of 20–70 hours, but its primary active metabolite — desmethyldiazepam (nordiazepam) — has a half-life of 36–200 hours, meaning the drug can accumulate substantially with repeated use and take days to fully clear the system.
Diazepam is highly lipid-soluble, which produces rapid CNS penetration after an oral dose (fast onset) but also means the drug rapidly redistributes from the brain to body fat — producing a relatively short initial duration of effect despite a long half-life. This paradox is clinically important. Diazepam is FDA-approved for anxiety, muscle spasm, alcohol withdrawal, and as an adjunct in seizure disorders. It is also available in rectal gel (Diastat) and nasal spray (Valtoco) formulations for acute repetitive seizures.
Clonazepam is a high-potency, long-acting benzodiazepine with an unusually broad set of clinical approvals. It is one of the few benzodiazepines FDA-approved for use as an anticonvulsant — specifically for absence seizures (petit mal), Lennox-Gastaut syndrome, myoclonic seizures, and akinetic seizures — in addition to panic disorder. Its long half-life (18–50 hours) with no significant active metabolites makes it useful for providing stable, sustained drug levels for seizure prevention.
Clonazepam is also commonly used off-label for restless legs syndrome, REM sleep behavior disorder, and certain movement disorders. Its high potency and long duration mean physical dependence develops readily and withdrawal can be prolonged and challenging. Available as regular tablets and orally disintegrating tablets (Klonopin Wafers); generic clonazepam is widely available.
Lorazepam occupies a distinctive place in clinical practice because it is one of the most reliably absorbed benzodiazepines when administered parenterally (IV or IM) and is a first-line treatment for status epilepticus in hospital settings. Its intermediate half-life (10–20 hours), absence of active metabolites, and reliable IV pharmacokinetics make it the preferred benzodiazepine in many emergency and critical care scenarios, including acute seizures, procedural sedation, severe agitation, and ICU sedation protocols.
Orally, lorazepam is used for anxiety, preoperative sedation, and sleep. It undergoes direct glucuronidation — the same simpler metabolic pathway as oxazepam — making it safer than diazepam in patients with liver disease or elderly patients where CYP450 metabolism may be impaired. No significant active metabolites means it does not accumulate with repeated dosing in the way diazepam does. Generic lorazepam is widely available in oral and injectable forms.
Oxazepam is a pharmacologically simple benzodiazepine with a short-to-intermediate half-life and — crucially — no active metabolites. It undergoes direct glucuronidation (conjugation), bypassing the CYP450 hepatic enzyme system entirely. This makes it the preferred benzodiazepine in patients with significant liver disease (cirrhosis, hepatitis), in the elderly, and in patients taking multiple CYP450-metabolized medications. The mnemonic "LOT" (lorazepam, oxazepam, temazepam) identifies the benzodiazepines that undergo glucuronidation without active metabolites and are preferred in these patient populations.
Oxazepam's slower onset — it is one of the slowest-onset benzos in its class — means it is not useful for acute panic management but is appropriate for chronic anxiety or alcohol withdrawal in liver-impaired patients. Brand-name Serax is discontinued in the US; generic oxazepam remains available.
Temazepam is FDA-approved specifically for the short-term management of insomnia — it is one of the few benzodiazepines with an indication primarily for sleep rather than anxiety. Like oxazepam and lorazepam, temazepam undergoes glucuronidation without producing active metabolites, making it safer in elderly patients than benzodiazepines with long-acting metabolites. Its intermediate half-life (8–20 hours) allows sleep induction and maintenance without the prolonged next-day sedation that longer-acting benzodiazepines can produce.
Temazepam is taken shortly before bedtime. Like all benzodiazepines used for sleep, it carries risks of tolerance (reduced effectiveness for sleep with continued use), physical dependence, next-day psychomotor impairment, and rebound insomnia upon discontinuation. Generic temazepam is widely available.
Triazolam is the shortest-acting benzodiazepine used for sleep, with a very short half-life of 1.5–5 hours and rapid onset. Its ultra-short duration means it is less likely to produce next-morning sedation than intermediate- or long-acting sleep benzos. However, triazolam is associated with a higher frequency of anterograde amnesia — patients may not remember events that occurred after taking it — as well as rebound insomnia after even brief periods of use. The European Union has withdrawn triazolam from its market due to safety concerns; it remains available in the United States.
Triazolam is primarily indicated for sleep-onset insomnia (difficulty falling asleep) rather than sleep-maintenance insomnia (difficulty staying asleep). It is not appropriate for patients who need to wake and remain functional within a few hours of taking it. Available as branded Halcion; generic triazolam is available.
Chlordiazepoxide was the first benzodiazepine to reach the market (1960) and remains a first-line option for alcohol withdrawal management. Its long half-life (5–30 hours for the parent compound) and multiple active metabolites — including desmethylchlordiazepoxide and demoxepam, which are further metabolized to desmethyldiazepam (nordiazepam) and ultimately to oxazepam — provide prolonged, self-tapering drug levels that smooth the withdrawal process and reduce the risk of breakthrough seizures. This "built-in taper" effect is a clinical advantage for alcohol withdrawal management.
Because of its multiple active metabolites and complex, extended metabolism, chlordiazepoxide is not preferred in elderly patients or patients with significant liver disease — lorazepam or oxazepam are preferred in those populations. It is less commonly used for chronic anxiety management today than in the past. Brand-name Librium is discontinued; generic chlordiazepoxide is available.
Clorazepate is unique among benzodiazepines in that it is a prodrug: it is not pharmacologically active itself. After oral ingestion, it is hydrolyzed in the acidic environment of the stomach to desmethyldiazepam (nordiazepam), the same primary active metabolite of diazepam. Nordiazepam has a half-life of 36–200 hours, making clorazepate effectively a long-acting benzodiazepine with all the properties of desmethyldiazepam. Subsequent metabolism proceeds through oxazepam to glucuronide conjugates.
Clorazepate is FDA-approved for anxiety disorders, alcohol withdrawal, and as an adjunct in the management of partial seizures. Because its activity derives entirely from conversion to desmethyldiazepam, its onset is somewhat dependent on gastric pH — antacids can delay conversion and alter absorption. Available as generic clorazepate dipotassium tablets.
Midazolam is a water-soluble, ultra-short-acting benzodiazepine used almost exclusively in hospital, procedural, and emergency settings — it is not used for chronic anxiety or routine outpatient indications. Its extremely short half-life (1–4 hours), rapid IV onset (within minutes), and potent amnestic properties make it the standard benzodiazepine for conscious sedation, endoscopy and bronchoscopy procedures, preoperative sedation, and as a first-line agent for pediatric and adult status epilepticus when IV access is available.
Midazolam nasal spray (Nayzilam) and midazolam IM autoinjector (Seizalam) are approved for acute repetitive seizures in outpatient settings. Midazolam's amnestic effect is profound and reliable — patients typically have no memory of procedures performed under its influence, which is both therapeutically useful and clinically relevant. Available as injectable, nasal spray, and oral syrup for pediatric procedures. Brand-name Versed is discontinued; generic midazolam injectable is standard hospital use.
Quick Reference: All Major Benzodiazepines at a Glance
| Brand | Generic | Half-Life | Onset | Potency* | Active Metabolites | Main Use | Available Strengths | Schedule |
|---|---|---|---|---|---|---|---|---|
| Short-Acting (<12 h half-life) | ||||||||
| Halcion | triazolam | 1.5–5 h | 15–30 min | High | No | Sleep-onset insomnia | 0.125, 0.25 mg tabs | C-IV |
| Versed | midazolam | 1–4 h | IV: 1–5 min | High | Minor | Procedural sedation | Injectable, nasal, oral syrup | C-IV |
| Xanax | alprazolam | 6–12 h | 15–30 min | High | No | Anxiety, panic disorder | 0.25, 0.5, 1, 2 mg tabs; XR 0.5–3 mg | C-IV |
| Intermediate-Acting (12–24 h half-life) | ||||||||
| Serax | oxazepam | 5–15 h | 45–90 min | Low–Moderate | No | Anxiety, alcohol withdrawal (liver disease) | 10, 15, 30 mg caps | C-IV |
| Restoril | temazepam | 8–20 h | 30–60 min | Moderate | No | Insomnia | 7.5, 15, 22.5, 30 mg caps | C-IV |
| Ativan | lorazepam | 10–20 h | 15–30 min (oral) | High | No | Anxiety, seizures (IV), sedation | 0.5, 1, 2 mg tabs; injectable | C-IV |
| Long-Acting (>24 h half-life) | ||||||||
| Klonopin | clonazepam | 18–50 h | 20–60 min | High | No | Panic disorder, seizures | 0.5, 1, 2 mg tabs; ODT wafers | C-IV |
| Valium | diazepam | 20–70 h (+metabolites) | 15–60 min | Low (reference) | Yes (nordiazepam 36–200 h) | Anxiety, muscle spasm, alcohol withdrawal | 2, 5, 10 mg tabs; solution; rectal; nasal | C-IV |
| Librium | chlordiazepoxide | 5–30 h (+metabolites) | 30–60 min | Low | Yes (multiple, including nordiazepam) | Alcohol withdrawal, anxiety | 5, 10, 25 mg caps | C-IV |
| Tranxene | clorazepate | Prodrug → nordiazepam 36–200 h | 30–60 min | Moderate | Yes (is converted to nordiazepam) | Anxiety, alcohol withdrawal, partial seizures | 3.75, 7.5, 15 mg tabs | C-IV |
*Potency relative to diazepam: Low = requires more mg than diazepam per equivalent effect; High = requires less mg than diazepam per equivalent effect.
Patient Selection by Indication
The clinical choice of benzodiazepine is rarely arbitrary. Matching pharmacokinetic properties to the clinical situation — and the patient's individual characteristics — is a key principle of rational prescribing.
- Alprazolam (Xanax) — rapid relief; high abuse potential
- Clonazepam (Klonopin) — stable long-acting; less rebound
- Lorazepam (Ativan) — intermediate option
- Diazepam (Valium) — smooth long-acting; accumulates
- Note: SSRIs/SNRIs are first-line for chronic anxiety
- Temazepam (Restoril) — FDA-approved for sleep; intermediate
- Triazolam (Halcion) — sleep onset; ultra-short; amnesia risk
- Z-drugs (zolpidem, zaleplon, eszopiclone) — often preferred for sleep
- Caution: tolerance to sleep effects develops within weeks
- Clonazepam (Klonopin) — oral anticonvulsant; absence, myoclonic
- Lorazepam (Ativan) IV — first-line for status epilepticus
- Midazolam (Versed) — IV/IM/nasal for status epilepticus
- Diazepam rectal/nasal — acute repetitive seizures at home
- Clorazepate — adjunct for partial seizures
- Diazepam (Valium) — long-acting; smooth offset; preferred if no liver disease
- Chlordiazepoxide (Librium) — self-tapering via active metabolites
- Lorazepam (Ativan) — preferred if liver disease or elderly
- Oxazepam (Serax) — preferred in liver disease; slower onset
- Managed by CIWA protocol in clinical settings
- Diazepam (Valium) — FDA-approved for muscle spasm
- Adjunct to rest, physical therapy, and other measures
- Non-benzo muscle relaxants often preferred long-term
- Midazolam (Versed) — gold standard; IV/IM/nasal
- Lorazepam (Ativan) — IV alternative in some hospital protocols
- Both provide reliable anxiolysis and anterograde amnesia
- Requires monitoring; reversal agent flumazenil available
Diazepam Equivalency Guide
Diazepam equivalents are a clinical tool used primarily for understanding the relative potency of different benzodiazepines and for designing tapering schedules when transitioning patients from one benzodiazepine to another (for example, from a short-acting to a long-acting benzo for a managed taper). These are approximate equivalences for patient education purposes — actual clinical dose conversions must be supervised by a prescriber and individualized to the patient.
| Benzodiazepine | Approximate Oral Equivalence | Notes |
|---|---|---|
| Diazepam (Valium) | 10 mg | Reference standard |
| Chlordiazepoxide (Librium) | 25 mg | Lower potency; multiple active metabolites |
| Clorazepate (Tranxene) | 15 mg | Prodrug; converted to nordiazepam |
| Oxazepam (Serax) | 20–30 mg | No active metabolites; slow onset |
| Lorazepam (Ativan) | 1–2 mg | High potency; no active metabolites |
| Alprazolam (Xanax) | 0.5–1 mg | High potency; short-acting |
| Clonazepam (Klonopin) | 0.5 mg | Very high potency; long-acting |
| Temazepam (Restoril) | 20 mg | Intermediate potency; sleep use |
| Triazolam (Halcion) | 0.25 mg | High potency; ultra-short |
| Midazolam (Versed) | Not applicable (parenteral/procedural use) | Context-dependent; parenteral conversion required |
⚠ Diazepam equivalent conversions are approximate and should never be used to self-adjust medications. Conversions between benzodiazepines must be performed under medical supervision — errors in potency conversion can cause withdrawal seizures or dangerous over-sedation.
Risks, Warnings, and Safety Considerations
Dependence and Tolerance
Physical dependence on benzodiazepines can develop with as little as 2–4 weeks of daily use at standard therapeutic doses. This is not the same as addiction — physical dependence is a physiological adaptation in which the body requires the drug to maintain normal function. Addiction involves compulsive drug-seeking behavior despite negative consequences. Many patients who are physically dependent on benzodiazepines prescribed by a physician are not addicted in the clinical sense, but they still require a supervised taper to discontinue the medication safely. Tolerance to sedative and euphoric effects develops faster than tolerance to anxiolytic effects.
Withdrawal: Can Be Fatal
⚠ BENZODIAZEPINE WITHDRAWAL IS POTENTIALLY FATAL. Unlike opioid withdrawal (which is rarely life-threatening in healthy adults), benzo withdrawal shares with alcohol withdrawal the risk of grand mal seizures and death. This risk is heightened with high-potency, short-acting benzodiazepines (like alprazolam) stopped abruptly after prolonged use, and with high doses. Standard management involves switching to a longer-acting benzodiazepine (typically diazepam) and implementing a slow taper — reducing by no more than 5–10% every 1–2 weeks. The Ashton Manual is a widely referenced clinical guide for long-term benzo tapering strategies.
Overdose and the Opioid Combination
Benzodiazepines alone, in an otherwise healthy adult, are rarely lethal in overdose because they require GABA to be present to produce their effect — they cannot completely shut down respiratory drive independently. However, benzodiazepines combined with opioids, alcohol, or other CNS depressants are highly dangerous and frequently fatal. The opioid-benzo combination was identified by the FDA as a primary driver of overdose deaths and prompted mandatory black box warnings on both drug classes. Flumazenil is a benzodiazepine reversal agent available in hospital settings but is rarely used clinically due to its very short duration (benzo effects typically outlast flumazenil) and risk of precipitating seizures in benzodiazepine-dependent patients.
Elderly Patients — Falls and Cognitive Effects
All benzodiazepines are included in the American Geriatrics Society Beers Criteria as medications to avoid or use with extreme caution in adults aged 65 and older. The reasons include increased risk of falls and hip fractures (due to sedation and impaired balance), cognitive impairment (which may be mistaken for dementia), delirium, and prolonged drug accumulation due to decreased hepatic metabolism and reduced renal clearance in older adults. Long-acting benzodiazepines with active metabolites (diazepam, chlordiazepoxide) are particularly problematic in the elderly. When use is unavoidable, shorter-acting agents without active metabolites (lorazepam, oxazepam, temazepam) are preferred, though all carry risks.
Pregnancy
Benzodiazepine use during pregnancy is associated with several risks. Older data linked first-trimester exposure to cleft palate risk, though more recent studies have yielded mixed results. Third-trimester use can cause neonatal withdrawal syndrome — the newborn may experience tremors, irritability, poor feeding, and respiratory depression after birth as the drug clears from the baby's system. Benzodiazepines cross the placenta and are also present in breast milk. If benzodiazepine use during pregnancy is unavoidable, this requires careful individualized risk-benefit analysis with a prescribing provider and, ideally, an obstetrician or maternal-fetal medicine specialist.
Z-Drugs: Related but Not True Benzodiazepines
The "Z-drugs" — zolpidem (Ambien), zaleplon (Sonata), and eszopiclone (Lunesta) — are non-benzodiazepine hypnotics that act on the same GABA-A receptor as benzodiazepines, but bind selectively to the alpha-1 subunit, which is associated primarily with sedative effects. This selectivity was initially believed to produce fewer side effects and lower dependence potential than traditional benzodiazepines. In practice, the differences are modest: Z-drugs can cause dependence, withdrawal, and rebound insomnia, and they share many of the same risks.
| Brand | Generic | Half-Life | Available Strengths | Schedule | Notes |
|---|---|---|---|---|---|
| Ambien / Ambien CR | zolpidem | IR: 2.5 h; CR: 2.8 h | IR: 5, 10 mg; CR: 6.25, 12.5 mg | C-IV | Most widely prescribed sleep medication in the US; complex sleep behaviors (sleepwalking, sleep-driving) reported; FDA reduced recommended doses in 2013 |
| Sonata | zaleplon | ~1 h (ultra short) | 5, 10 mg capsules | C-IV | Ultra-short half-life; minimal next-morning impairment; useful for sleep-onset only; can be taken in the middle of the night if >4 h remain before waking |
| Lunesta | eszopiclone | 6 h | 1, 2, 3 mg tablets | C-IV | Longest duration among Z-drugs; approved for sleep onset and maintenance; metallic/bitter taste is common side effect |
A critical difference from true benzodiazepines: Z-drugs do not have significant anxiolytic, anticonvulsant, or muscle-relaxant properties at sleep doses — their clinical utility is almost entirely confined to insomnia management.
Frequently Asked Questions
Are all benzodiazepines the same?
No. While all benzodiazepines share the same fundamental mechanism — positive allosteric modulation of the GABA-A receptor — they differ substantially in potency, onset speed, half-life, the presence or absence of active metabolites, lipid solubility, and specific FDA-approved uses. A short-acting, high-potency benzo like alprazolam (Xanax) behaves very differently in clinical practice from a long-acting, low-potency benzo like diazepam (Valium). These differences determine which benzodiazepine is appropriate for a given patient and clinical situation. Selecting a benzodiazepine requires matching the drug's pharmacokinetic profile to the clinical need — not all benzos are interchangeable.
Which benzodiazepine is the safest?
No benzodiazepine is universally "safest" — the appropriate choice depends on the clinical context and the specific patient. For patients with liver disease, oxazepam (Serax), lorazepam (Ativan), and temazepam (Restoril) are preferred because they undergo glucuronidation without producing active metabolites that accumulate when liver metabolism is impaired. For elderly patients, shorter-acting agents without active metabolites are preferred to minimize accumulation and fall risk. However, all benzodiazepines carry fall and cognitive impairment risks in older adults and are listed on the Beers Criteria. In general, the lowest effective dose for the shortest necessary duration is the safest approach with any benzodiazepine.
How long does tolerance take to develop with benzodiazepines?
Tolerance to the sedating and euphoric effects of benzodiazepines can develop within days to a few weeks of regular use. Tolerance to the anxiolytic effects develops more slowly — typically over weeks to months of daily use. Tolerance to the anticonvulsant effects also develops, which is why benzodiazepines are generally not used as first-line long-term seizure medications (except clonazepam for certain seizure types). Physical dependence — the physiological adaptation that causes withdrawal when the drug is stopped — can develop with just 2–4 weeks of regular therapeutic use.
What is benzodiazepine withdrawal?
Benzodiazepine withdrawal is one of the only drug withdrawal syndromes that can be fatal, along with alcohol and barbiturate withdrawal. When the GABA-A-enhancing effect of benzodiazepines is abruptly removed after the brain has adapted to their presence, excitatory neurotransmitters become unopposed — potentially causing anxiety, tremors, sweating, heart palpitations, and in severe cases, grand mal seizures and death. The severity and timeline depend on the specific benzodiazepine used (its half-life determines how fast it leaves the system), the dose, and the duration of use. Medical management involves a slow, supervised taper — typically substituting a long-acting benzodiazepine and reducing by 5–10% every 1–2 weeks or slower. The Ashton Manual is a widely referenced resource on tapering. Self-managed cold-turkey withdrawal from high-dose or long-term benzodiazepine use is dangerous and should never be attempted.